Physician profile
Angela Applebee
NPI 1508051517
$536,692.62
in general payments reported to CMS, 2019-2025
35 companies · $80K in 2025
The $80K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110K · 2020: $63K · 2021: $62K · 2022: $90K · 2023: $74K · 2024: $59K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $175K · Consulting Fee: $24K · Food and Beverage: $7,470 · Travel and Lodging: $5,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $175,451.00 |
| Consulting Fee | $23,830.96 |
| Food and Beverage | $7,470.26 |
| Travel and Lodging | $5,693.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $188,614.67 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $131,533.36 | 2019-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $90,027.36 | 2019-2025 | |
| Genentech USA, INC. | $88,650.98 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $12,889.90 | 2019-2024 | Kesimpta |
| Celgene Corporation | $9,172.52 | 2019-2023 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $6,210.03 | 2020-2024 | Zeposia |
| Abbvie INC. | $3,939.79 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Alexion Pharmaceuticals, INC. | $1,880.40 | 2019-2025 | Ultomiris |
| Horizon Therapeutics Plc | $1,789.02 | 2022 | |
| Tg Therapeutics, INC. | $873.73 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $237.07 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $199.01 | 2021-2022 | |
| Amgen INC. | $108.04 | 2021-2025 | Uplizna |
| Lundbeck LLC | $71.60 | 2022-2023 | Vyepti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $58.70 | 2022 | |
| Lilly USA, LLC | $48.44 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $37.52 | 2020-2022 | |
| Harmony Biosciences LLC | $36.72 | 2023 | Wakix |
| Scilex Pharmaceuticals INC. | $33.96 | 2025 | |
| Pfizer INC. | $32.56 | 2023 | |
| Neurocrine Biosciences, INC. | $28.00 | 2023 | Ongentys, Ingrezza |
| Ani Pharmaceuticals, INC. | $24.85 | 2022 | |
| Eisai INC. | $23.02 | 2023 | |
| Livanova USA, INC. | $22.44 | 2022 | |
| Mylan Specialty L.P. | $20.64 | 2023 | Glatiramer Acetate |
| Otsuka America Pharmaceutical, INC. | $20.41 | 2023 | Nuedexta |
| Sk Life Science, INC. | $19.70 | 2022 | |
| Banner Life Sciences, LLC | $19.44 | 2021 | |
| Impel Pharmaceuticals LLC | $18.22 | 2025 | Trudhesa |
| Impel Pharmaceuticals INC. | $17.14 | 2022 | |
| Allergan, INC. | $15.38 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.36 | 2022 | |
| Genentech, INC. | $2.64 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Applebee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.